Hepatocellular carcinoma (HCC) is one of the most commonly diagnosed cancers worldwide. Majority of patients with HCC are diagnosed in the advanced stages of disease and hence they are only suitable for palliative therapy. TACE (transarterial chemoembolization) is the most commonly used treatment for unresectable HCC. It is however unclear if TACE improves the quality of life (QoL) in patients with HCC. The aim of this review is to evaluate the impact of TACE on QoL of HCC patients.
Keyphrases
- radiofrequency ablation
- end stage renal disease
- liver metastases
- ejection fraction
- chronic kidney disease
- palliative care
- prognostic factors
- peritoneal dialysis
- squamous cell carcinoma
- stem cells
- patient reported outcomes
- mesenchymal stem cells
- radiation therapy
- advanced cancer
- replacement therapy
- combination therapy
- cell therapy